Silexion Advances SIL204 into Phase 2/3 Trials with Israeli and EU Approvals
Event summary
- Israeli Ministry of Health approved Phase 2/3 trial of SIL204 for locally advanced pancreatic cancer on March 24, 2026.
- Submitted Clinical Trial Application to Germany via EU Clinical Trials Information System on April 28, 2026.
- Phase 2/3 trial initiation remains on track for Q2 2026, with a safety run-in cohort of 18 patients and a randomized cohort of 166 patients.
- Q1 2026 R&D expenses increased 133.3% YoY to $1.4M, driven by toxicology studies and GMP manufacturing.
- Cash and cash equivalents decreased to $2.4M as of March 31, 2026, from $6.0M as of December 31, 2025.
The big picture
Silexion's progress in advancing SIL204 into Phase 2/3 trials marks a significant milestone in the development of RNAi therapies for KRAS-driven cancers, particularly pancreatic cancer. The company's ability to secure approvals in Israel and submit applications in the EU demonstrates its strategic focus on expanding its clinical footprint. However, the substantial increase in R&D expenses and the decline in cash position highlight the financial challenges of sustaining clinical development efforts.
What we're watching
- Trial Execution
- Whether Silexion can successfully initiate and conduct the Phase 2/3 trial of SIL204 in Q2 2026 across Israel and the EU.
- Financial Sustainability
- The pace at which Silexion can raise additional capital to support its clinical development plan and maintain Nasdaq listing compliance.
- Regulatory Momentum
- How the approvals from Israel and the submission to Germany will impact the timeline for potential regulatory approvals in other jurisdictions.
Related topics